Antonio Giordano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antonio Giordano has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
- Feng Liu
Pfizer Inc., San Diego, CA, USA
17 shared publications - Allison Moreau
10Pfizer Inc., La Jolla, California
16 shared publications - Antoaneta Tomova
Complex Oncology Center Plovdiv, Plovdiv, Bulgaria
16 shared publications - Erika Hamilton
Sarah Cannon Research Institute, Nashville, TN, USA
16 shared publications - Heather Neumann
10Pfizer Inc., La Jolla, California
16 shared publications - Igor Bondarenko
Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine
16 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (20)
Next-generation CDK inhibitors in HR+/HER2– breast cancer
Cell-cycle dysregulation is a central driver of breast cancer progression and a major therapeutic vulnerability, particularly in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR + /HER2 – ) disease. The clinical success of cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy has transformed treatment paradigms and established cell-cycle targeting as a cornerstone of care. However, important challenges remain, including hematologic toxicity, incomplete and largely cytostatic responses, and the near-universal development of resistance. These limitations have highlighted the need for next-generation CDK-directed strategies capable of improving selectivity, extending disease control, and overcoming adaptive escape pathways. This Review examines the evolving landscape of CDK-targeted therapeutics in breast cancer, with particular emphasis on emerging CDK4-selective inhibitors, CDK2-directed approaches, and broader multi-CDK strategies. We discuss the biological rationale underpinning these agents, the mechanisms of resistance that have informed their development, and the clinical opportunities they may create across both advanced and early-stage settings. By refining target specificity and addressing resistance-associated cell-cycle rewiring, next-generation CDK inhibitors may reduce toxicity, enhance treatment durability, and enable more effective combination and sequencing strategies. Collectively, these advances promise to move breast cancer treatment beyond current CDK4/6 inhibition toward more precise, adaptable, and durable cell-cycle–directed therapy.
- 15 October 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (20)
Open AccessNext-generation CDK inhibitors in HR+/HER2– breast cancer
Cell-cycle dysregulation is a central driver of breast cancer progression and a major therapeutic vulnerability, particularly in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR + /HER2 – ) disease. The clinical success of cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy has transformed treatment paradigms and established cell-cycle targeting as a cornerstone of care. However, important challenges remain, including hematologic toxicity, incomplete and largely cytostatic responses, and the near-universal development of resistance. These limitations have highlighted the need for next-generation CDK-directed strategies capable of improving selectivity, extending disease control, and overcoming adaptive escape pathways. This Review examines the evolving landscape of CDK-targeted therapeutics in breast cancer, with particular emphasis on emerging CDK4-selective inhibitors, CDK2-directed approaches, and broader multi-CDK strategies. We discuss the biological rationale underpinning these agents, the mechanisms of resistance that have informed their development, and the clinical opportunities they may create across both advanced and early-stage settings. By refining target specificity and addressing resistance-associated cell-cycle rewiring, next-generation CDK inhibitors may reduce toxicity, enhance treatment durability, and enable more effective combination and sequencing strategies. Collectively, these advances promise to move breast cancer treatment beyond current CDK4/6 inhibition toward more precise, adaptable, and durable cell-cycle–directed therapy.
- Top Cited PapersOpen Access
- 20 April 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (12) , 1108-1119
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
PURPOSE: Gedatolisib potently targets all four class I PI3K isoforms and mTORC1 and mTORC2 to comprehensively block the PI3K/AKT/mTOR pathway and has shown compelling activity in early clinical trials with palbociclib and fulvestrant. METHODS: This phase III randomized trial (VIKTORIA-1; ClinicalTrials.gov identifier: NCT05501886 ) evaluated the efficacy of gedatolisib-based therapy, comparing gedatolisib, palbociclib, and fulvestrant (gedatolisib triplet) and gedatolisib plus fulvestrant (gedatolisib doublet) with fulvestrant monotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HER2−), PIK3CA wild-type (WT) advanced breast cancer. Eligible patients had disease progression during or after CDK4/6 inhibitor and aromatase inhibitor treatment. Comparison of progression-free survival as assessed by blinded independent central review for gedatolisib triplet versus fulvestrant and gedatolisib doublet versus fulvestrant was the primary objective. RESULTS: A total of 392 patients were randomly assigned 1:1:1. The median study follow-up was 10.1 months. The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant). Grade ≥3 treatment-related adverse events (TRAEs) reported in the gedatolisib-triplet and gedatolisib-doublet groups, respectively, included neutropenia (62.3%, 0.8%), stomatitis (19.2%, 12.3%), rash (4.6%, 5.4%), hyperglycemia (2.3%, 2.3%), and diarrhea (1.5%, 0.8%). Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients. CONCLUSION: The addition of gedatolisib to fulvestrant, with or without palbociclib, significantly reduced the risk of disease progression or death in patients with hormone receptor–positive/HER2−, PIK3CA WT advanced breast cancer.
- 20 April 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (12) , 1108-1119
Top Cited PapersOpen AccessVIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
PURPOSE: Gedatolisib potently targets all four class I PI3K isoforms and mTORC1 and mTORC2 to comprehensively block the PI3K/AKT/mTOR pathway and has shown compelling activity in early clinical trials with palbociclib and fulvestrant. METHODS: This phase III randomized trial (VIKTORIA-1; ClinicalTrials.gov identifier: NCT05501886 ) evaluated the efficacy of gedatolisib-based therapy, comparing gedatolisib, palbociclib, and fulvestrant (gedatolisib triplet) and gedatolisib plus fulvestrant (gedatolisib doublet) with fulvestrant monotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HER2−), PIK3CA wild-type (WT) advanced breast cancer. Eligible patients had disease progression during or after CDK4/6 inhibitor and aromatase inhibitor treatment. Comparison of progression-free survival as assessed by blinded independent central review for gedatolisib triplet versus fulvestrant and gedatolisib doublet versus fulvestrant was the primary objective. RESULTS: A total of 392 patients were randomly assigned 1:1:1. The median study follow-up was 10.1 months. The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant). Grade ≥3 treatment-related adverse events (TRAEs) reported in the gedatolisib-triplet and gedatolisib-doublet groups, respectively, included neutropenia (62.3%, 0.8%), stomatitis (19.2%, 12.3%), rash (4.6%, 5.4%), hyperglycemia (2.3%, 2.3%), and diarrhea (1.5%, 0.8%). Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients. CONCLUSION: The addition of gedatolisib to fulvestrant, with or without palbociclib, significantly reduced the risk of disease progression or death in patients with hormone receptor–positive/HER2−, PIK3CA WT advanced breast cancer.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Enfortumab Vedotin in Patients With Previously Treated Advanced Breast Cancer in the Phase II EV-202 Study
PURPOSE: EV-202 (ClinicalTrials.gov identifier: NCT04225117 ) evaluated enfortumab vedotin (EV), a nectin-4–directed antibody-drug conjugate, in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) and triple-negative breast cancer (TNBC). METHODS: This open-label, multicohort, Phase II study included eligible adults with locally advanced or metastatic (la/m) BC who had progressed, relapsed, or discontinued for toxicity during or after ≥1 previous standard-of-care cytotoxic regimen in the incurable, unresectable la/m setting, and had not received >2 previous lines of cytotoxic therapy in the la/m setting. Patients had received previous endocrine treatment (HR+/HER2−) or PD-1/L1 inhibitor if eligible (TNBC). Patients received EV 1.25 mg/kg intravenously on days 1, 8, and 15 of 28-day cycles. The primary end point was investigator-assessed confirmed objective response rate (ORR) per RECIST v1.1. Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Forty-five women with HR+/HER2− BC received EV. Confirmed ORR and DCR were 15.6% and 51.1%, respectively. Median DOR, PFS, and OS were 7.23, 5.39, and 19.75 months, respectively. Twenty patients experienced grade ≥3 treatment-related adverse events (TRAEs), most commonly, rash maculopapular (n = 7, 16%), pruritus, and increased AST (both n = 3, 7%). Forty-two women with TNBC received EV. Confirmed ORR and DCR were 19.0% and 57.1%, respectively. Median DOR, PFS, and OS were 3.78, 3.52, and 12.91 months, respectively. Twelve patients experienced grade ≥3 TRAEs, most commonly, decreased neutrophil count (n = 3, 7%). CONCLUSION: Although EV showed antitumor activity in heavily pretreated HR+/HER2− BC and TNBC, efficacy did not meet the prespecified threshold. The safety profile was consistent with previous reports. A trend was not observed between nectin-4 and patient response.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Enfortumab Vedotin in Patients With Previously Treated Advanced Breast Cancer in the Phase II EV-202 Study
PURPOSE: EV-202 (ClinicalTrials.gov identifier: NCT04225117 ) evaluated enfortumab vedotin (EV), a nectin-4–directed antibody-drug conjugate, in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) and triple-negative breast cancer (TNBC). METHODS: This open-label, multicohort, Phase II study included eligible adults with locally advanced or metastatic (la/m) BC who had progressed, relapsed, or discontinued for toxicity during or after ≥1 previous standard-of-care cytotoxic regimen in the incurable, unresectable la/m setting, and had not received >2 previous lines of cytotoxic therapy in the la/m setting. Patients had received previous endocrine treatment (HR+/HER2−) or PD-1/L1 inhibitor if eligible (TNBC). Patients received EV 1.25 mg/kg intravenously on days 1, 8, and 15 of 28-day cycles. The primary end point was investigator-assessed confirmed objective response rate (ORR) per RECIST v1.1. Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Forty-five women with HR+/HER2− BC received EV. Confirmed ORR and DCR were 15.6% and 51.1%, respectively. Median DOR, PFS, and OS were 7.23, 5.39, and 19.75 months, respectively. Twenty patients experienced grade ≥3 treatment-related adverse events (TRAEs), most commonly, rash maculopapular (n = 7, 16%), pruritus, and increased AST (both n = 3, 7%). Forty-two women with TNBC received EV. Confirmed ORR and DCR were 19.0% and 57.1%, respectively. Median DOR, PFS, and OS were 3.78, 3.52, and 12.91 months, respectively. Twelve patients experienced grade ≥3 TRAEs, most commonly, decreased neutrophil count (n = 3, 7%). CONCLUSION: Although EV showed antitumor activity in heavily pretreated HR+/HER2− BC and TNBC, efficacy did not meet the prespecified threshold. The safety profile was consistent with previous reports. A trend was not observed between nectin-4 and patient response.
- Open Access
- 1 October 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 89, 103535
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis
- 1 October 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 89, 103535
Open AccessEfficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Supplementary Figure S1. Change from baseline in tumor biomarkers following monotherapy or combination treatment - biomarker analysis set.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Supplementary Figure S1. Change from baseline in tumor biomarkers following monotherapy or combination treatment - biomarker analysis set.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Summary of DLT by system organ class and preferred term (all causalities). DLT—evaluable analysis set.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Summary of DLT by system organ class and preferred term (all causalities). DLT—evaluable analysis set.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Table 4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Summary of best overall response and objective response (confirmed) based on investigator assessment (RECIST version 1.1)—response-evaluable set, part 2.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Summary of best overall response and objective response (confirmed) based on investigator assessment (RECIST version 1.1)—response-evaluable set, part 2.